Kymera Therapeutics’ (KYMR) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report released on Tuesday,Benzinga reports. BTIG Research currently has a $138.00 target price on the stock.

Several other research firms have also recently commented on KYMR. Stifel Nicolaus set a $114.00 target price on shares of Kymera Therapeutics in a research note on Monday, December 8th. Bank of America increased their price objective on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Morgan Stanley raised their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Stephens upped their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Buy” and a consensus price target of $117.00.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $77.22 on Tuesday. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of -21.51 and a beta of 2.21. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The stock has a 50-day simple moving average of $76.05 and a 200 day simple moving average of $60.35.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The business had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. On average, equities research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Activity

In related news, insider Jared Gollob sold 49,307 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the transaction, the insider directly owned 109,992 shares in the company, valued at $9,752,990.64. This represents a 30.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 420,895 shares of company stock valued at $37,778,351. Corporate insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. bought a new position in Kymera Therapeutics in the third quarter worth $31,622,000. China Universal Asset Management Co. Ltd. increased its position in shares of Kymera Therapeutics by 77.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after purchasing an additional 10,052 shares during the last quarter. Frontier Capital Management Co. LLC raised its holdings in Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after purchasing an additional 359,847 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Kymera Therapeutics by 26.3% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after purchasing an additional 22,392 shares during the period. Finally, Atika Capital Management LLC bought a new stake in Kymera Therapeutics during the 2nd quarter valued at approximately $6,398,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.